Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study
This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting vaccination benefits amidst immunocompromised risks.